Piotr M. Czerski
A5015522761- Bipolar Disorder and Treatment
- Genetic Associations and Epidemiology
- Genetics and Neurodevelopmental Disorders
- Genetic Syndromes and Imprinting
- Autism Spectrum Disorder Research
- Adolescent and Pediatric Healthcare
- Tryptophan and brain disorders
- Neurotransmitter Receptor Influence on Behavior
- Schizophrenia research and treatment
- Attention Deficit Hyperactivity Disorder
- Genomic variations and chromosomal abnormalities
- Nerve injury and regeneration
- Child and Adolescent Psychosocial and Emotional Development
- Diet and metabolism studies
- Epigenetics and DNA Methylation
- Suicide and Self-Harm Studies
- Receptor Mechanisms and Signaling
- Genomics and Rare Diseases
- Stress Responses and Cortisol
- Digestive system and related health
- Prenatal Screening and Diagnostics
- Phosphodiesterase function and regulation
- Personality Disorders and Psychopathology
- Hormonal Regulation and Hypertension
- Human Health and Disease
Poznan University of Medical Sciences
2016-2025
Genomics (United Kingdom)
2022
Douglas College
2010
Centre Hospitalier Universitaire Sainte-Justine
2010
University of British Columbia
2010
McGill University
2010
University of Calgary
2010
University of Toronto
2010
Dalhousie University
2010
Douglas Mental Health University Institute
2010
Objective The assessment of response to lithium maintenance treatment in bipolar disorder (BD) is complicated by variable length treatment, unpredictable clinical course, and often inconsistent compliance. Prospective retrospective methods have been proposed the literature. In this study we report key phenotypic measures “Retrospective Criteria Long-Term Treatment Response Research Subjects with Bipolar Disorder” scale currently used Consortium on Lithium Genetics (ConLiGen) study. Materials...
Objective The purpose of this study was to identify genetic variants underlying the considerable individual differences in response antidepressant treatment. authors performed a genome-wide association analysis improvement depression severity with two drugs. Method High-quality Illumina Human610-quad chip genotyping data were available for 706 unrelated participants European ancestry treated major escitalopram (N=394) or nortriptyline (N=312) over 12-week period Genome-Based Therapeutic...
Abstract Borderline personality disorder (BOR) is determined by environmental and genetic factors, characterized affective instability impulsivity, diagnostic symptoms also observed in manic phases of bipolar (BIP). Up to 20% BIP patients show comorbidity with BOR. This report describes the first case–control genome-wide association study (GWAS) BOR, performed one largest BOR patient samples worldwide. The focus our analysis was (i) detect genes gene sets involved (ii) investigate overlap...
For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium effectively augment antidepressant drugs treatment of refractory major depressive episodes prevent relapses recurrent unipolar depression. In contrast many psychiatric drugs, outlasted various...
Background There have been conflicting reports on whether the length polymorphism in promoter of serotonin transporter gene (5-HTTLPR) moderates antidepressant effects selective reuptake inhibitors (SSRIs). We hypothesised that pharmacogenetic effect 5-HTTLPR is modulated by gender, age and other variants gene. Aims To test hypothesis differently influences response to escitalopram (an SSRI) compared with nortriptyline (a noradrenaline inhibitor). Method The 13 additional markers across were...
<h3>Importance</h3> Lithium is a first-line mood stabilizer for the treatment of bipolar affective disorder (BPAD). However, efficacy lithium varies widely, with nonresponse rate up to 30%. Biological response markers are lacking. Genetic factors thought mediate lithium, and there previously reported genetic overlap between BPAD schizophrenia (SCZ). <h3>Objectives</h3> To test whether polygenic score SCZ associated in explore potential molecular underpinnings this association. <h3>Design,...
ABSTRACT Bipolar disorder is a highly heritable psychiatric that features episodes of mania and depression. We performed the largest genome-wide association study to date, including 20,352 cases 31,358 controls European descent, with follow-up analysis 822 sentinel variants at loci P<1×10 -4 in an independent sample 9,412 137,760 controls. In combined analysis, 30 reached significant evidence for association, which 20 were novel. These contain genes encoding ion channels neurotransmitter...
Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action incompletely understood, and prediction outcomes limited. In our previous multi-omics study Pharmacogenomics Bipolar Disorder (PGBD) sample combining transcriptomic genomic data, we found that focal adhesion, extracellular matrix (ECM), PI3K-Akt signaling networks were associated with response to lithium. this study, replicated results using network propagation methods in a genome-wide...
Objectives: The aim of the study was to test a possible association between Val66Met polymorphism brain‐derived neurotrophic factor (BDNF) gene and performance on neurocognitive test, Wisconsin Card Sorting Test (WCST), in bipolar patients. Methods: Fifty‐four patients were studied, 18 male 36 female, aged 18–72 (mean 46 years). number perseverative errors (WCST‐P), non‐perseverative (WCST‐NP), completed corrected categories (WCST‐CC), conceptual level responses (WCST‐%CONC) set first...
OBJECTIVE: The authors previously reported an association between the D-amino acid oxidase activator (DAOA)/G30 locus and both schizophrenia bipolar affective disorder. Given presumed role of DAOA/G30 in neurochemistry psychosis its localization a disorder linkage region (13q34), it was hypothesized that finding would be mainly due to with psychotic features. METHOD: marker/haplotype associations obtained subset 173 patients features were similar those overall patient group, suggesting...
Abstract The measures of prefrontal cognition have been used as endophenotype in molecular‐genetic studies. Brain‐derived neurotrophic factor (BDNF) has implicated cognitive functions and the pathogenesis major psychoses. This study investigates relationship between Val66Met polymorphisms BDNF gene function 129 patients with schizophrenia 111 bipolar mood disorder. Cognitive tests included Wisconsin Card Sorting Test (WCST), such domains number perseverative errors, non‐perseverative...
Bipolar disorder (BD) is a highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. BD shows substantial clinical genetic overlap with other psychiatric disorders, in particular schizophrenia (SCZ). The genes underlying this etiological remain largely unknown. A recent SCZ genome wide association study (GWAS) the Psychiatric Genomics Consortium identified 128 independent genome-wide significant single nucleotide polymorphisms (SNPs). present...